Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Life sciences property investor to break new ground

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
A specialist new real estate investment trust is coming to the AIM market with a focus on UK life science properties in key innovation centres such as the university towns of Oxford and Cambridge and the St Pancras area of central London.
Life Science REIT is looking to raise £300 million to target property assets in what is known as the ‘Golden Triangle’, including laboratories, offices and co-working space, manufacturing and testing facilities and data centres, which should provide ‘strong potential for rental growth over the coming years’.
The trust has already identified £445 million of potential income-generating assets of which just over £300 million are already in exclusive talks or at an advanced stage of negotiation.
It is targeting a net asset value total return of more than 10% per year and an initial dividend yield of 4%, with the intention to increase the payout to 5% in the first couple of years. Leverage will be conservative, with a target loan to value ratio of between 30% and 40%.
Ironstone Asset Management, led by Simon Farnsworth, will advise the trust. With its first-mover advantage and focus on high-quality assets, the aim is to become ‘a first-stop for institutions and private investors alike seeking to add life science real estate exposure to their portfolios’.
The trust has a tiered advisory fee structure starting at 1.1% of NAV (net asset value) and declining to 0.75% of NAV as it grows in scale.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.